Fangsheng Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 268 million yuan, a year-on-year increase of 17.6%
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Fangsheng Pharmaceutical disclosed its third-quarter report for 2025. The company achieved revenue of 1.253 billion yuan in the first three quarters, a year-on-year decrease of 7.02%; the net profit attributable to shareholders of the listed company was 268 million yuan, a year-on-year increase of 17.6%; the net profit excluding non-recurring gains and losses was 213 million yuan, a year-on-year increase of 30.54%; the basic earnings per share were 0.61 yuan
According to the Zhitong Finance APP, Fangsheng Pharmaceutical (603998.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 1.253 billion yuan in the first three quarters, a year-on-year decrease of 7.02%; the net profit attributable to shareholders of the listed company was 268 million yuan, a year-on-year increase of 17.6%; the net profit excluding non-recurring gains and losses was 213 million yuan, a year-on-year increase of 30.54%; the basic earnings per share were 0.61 yuan